AngioDynamics, Inc. v. Biolitec AG

780 F.3d 429, 2015 U.S. App. LEXIS 3802, 2015 WL 1055519
CourtCourt of Appeals for the First Circuit
DecidedMarch 11, 2015
Docket14-1603
StatusPublished
Cited by41 cases

This text of 780 F.3d 429 (AngioDynamics, Inc. v. Biolitec AG) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
AngioDynamics, Inc. v. Biolitec AG, 780 F.3d 429, 2015 U.S. App. LEXIS 3802, 2015 WL 1055519 (1st Cir. 2015).

Opinion

STAHL, Circuit Judge.

This is a companion case to AngioDynamics v. Biolitec AG, Nos. 13-1626, 13-2179. In this appeal, Defendants challenge the district court’s exercise of personal jurisdiction over certain defendants, the denial of their motions to dismiss, and the entry of default judgment and a damages award against them as a sanction for discovery violations. Finding all arguments meritless, we affirm.

I. Facts & Background

This court previously set out the basic factual contours of this case in AngioDynamics, Inc. v. Biolitec AG, 711 F.3d 248 (1st Cir.2013) (per curiam). Plaintiff AngioDynamics, Inc. (“ADI”) obtained a $23 million judgment in New York against defendant Biolitec, Inc. (“BI”), a New Jersey corporation with its principal place of business in Massachusetts, based on an indemnification clause in the supply and distribu *432 tion agreement governing BI’s sale of medical equipment to ADI. Plaintiff sought to secure payment on that judgment by bringing suit in the District of Massachusetts against BI’s President and CEO, Wolfgang Neuberger, and its corporate parents, Biomed Technology Holdings (“Biomed”) and Biolitec AG (“BAG”) (collectively, “Defendants”), 1 alleging that Defendants had looted BI of over $18 million in assets in order to render it judgment-proof. Specifically, the complaint alleged tortious interference with contractual relations, fraudulent transfers of assets in violation of the Massachusetts Uniform Fraudulent Transfer Act (“MUFTA”), Mass. Gen. Laws ch. 109A, § 5, and deceptive commercial acts or practices in violation of Mass. Gen. Laws ch. 93A, § 11 (“chapter 93A”). The complaint also demanded a declaratory judgment that Neuberger, Biomed, and BAG were jointly and severally hable for ADI’s judgment against BI in the underlying contract action under the doctrine of piercing the corporate veil.

We will recount only the portions of the procedural background of this case pertinent to the issues raised in this appeal. ADI filed its amended complaint on March 26, 2010. BAG filed a motion to dismiss, averring that the district court lacked personal jurisdiction over the German company, and that three counts of ADI’s complaint failed to state a claim. The district court denied the motion in a lengthy memorandum and order. AngioDynamics, Inc. v. Biolitec AG, No. 09-cv-30181-MAP, 2011 WL 3157312, at *9 (D.Mass. July 25, 2011). Four days later, Biomed and Neuberger filed their own motion to dismiss, raising substantially similar arguments as BAG’S motion (personal jurisdiction as to Biomed, and failure to state a claim on three counts as to both Biomed and Neuberger). The district court denied this second motion on the same grounds as the first.

As the parties began discovery, Defendants resisted ADI’s efforts to depose Neuberger and other key witnesses. ADI served Neuberger with a notice of deposition in July ' 2012, but he indicated he would not attend. After ADI filed a motion to compel his attendance at the deposition, Neuberger agreed to come and ADI withdrew its motion. Neuberger attended the first day of the deposition in Springfield, Massachusetts, in January 2013, but the parties were forced to postpone the remainder of the deposition until Defendants produced various court-ordered documents for ADI’s review. In July 2013, Defendants filed a motion for a protective order to stay Neuberger’s deposition. The magistrate judge assigned to this case denied the motion as, inter alia, untimely and unfairly prejudicial to ADI. Defendants refused to produce Neuberger, and filed a second motion for a protective order seeking to continue the deposition by videolink; the magistrate judge denied this motion as well. Similar issues arose in relation to the depositions of three key BI corporate officers: the parties agreed to suspend their depositions until Defendants produced various court-ordered documents. Subsequently, Defendants refused to produce any of the documents or the three witnesses. ADI filed two motions for sanctions based on the Defendants’ failure *433 to turn over the key documents and refusal to produce either Neuberger or the three managing agents.

During the discovery period, ADI learned that Defendants planned to merge BAG with its Austrian subsidiary. ADI moved for a temporary restraining order and then for a preliminary injunction to prevent the merger, arguing that ADI would be unable to enforce any judgment against BAG in the Austrian courts. The district court enjoined the merger and this court affirmed the issuance of the preliminary injunction. AngioDynamics, 711 F.3d at 252. While that appeal was pending, Defendants effected the merger anyway. ADI moved for contempt proceedings, and the district court ordered Neuberger to appear in person to show cause why he should not be held in contempt. Neuberger did not appear. On April 11, 2013, the district court held Defendants in contempt for violating the preliminary injunction and ordered coercive penalties against Defendants until they undid the merger. AngioDynamics, Inc. v. Biolitec AG, 946 F.Supp.2d 205, 215-16 (D.Mass.2013). This contempt order is the subject of the companion case to this opinion, AngioDynamics v. Biolitec AG, Nos. 13-1626, 13-2179.

Approximately a month later, on May 24, 2013, ADI moved for default judgment based on Defendants’ failure to comply with the contempt order. The district court denied the motion on August 30, 2013, but ordered Defendants to file a status report detailing their plan for complying with the contempt decision and for producing Neuberger to the district court to “testify as to his actions in response to the injunction.” AngioDynamics, Inc. v. Biolitec AG, 966 F.Supp.2d 71, 74 (D.Mass. 2013). Defendants’ status report, dated October 1, 2013, stated definitively that they had no intention of complying with the contempt order. See Angiodynamics, Inc. v. Biolitec AG, 991 F.Supp.2d 283, 298 (D.Mass.2014). On October 11, 2013, ADI filed a renewed motion for default judgment based on Defendants’ status report, which the district court heard along with ADI’s two motions for sanctions for violations of various discovery orders. On January 14, 2014, the district court allowed the motions for sanctions and entered default judgment for ADI. 2 Id. at 299. On March 18, 2014, the court awarded approximately $75 million to ADI, which included chapter 93A damages. Angiodynamics, Inc. v. Biolitec AG, 991 F.Supp.2d 299, 307 (D.Mass.2014). This appeal followed.

II. Analysis

A. Personal Jurisdiction

Defendants begin by positing that the default judgment is void as to BAG, BI’s parent corporation, and Biomed, BAG’S primary shareholder, for lack of personal jurisdiction. 3

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
780 F.3d 429, 2015 U.S. App. LEXIS 3802, 2015 WL 1055519, Counsel Stack Legal Research, https://law.counselstack.com/opinion/angiodynamics-inc-v-biolitec-ag-ca1-2015.